A nonreplicating adenoviral vector that contains the wild-typep53 transgene combined with chemotherapy for primary breast cancer
Open Access
- 27 July 2006
- Vol. 107 (5), 935-944
- https://doi.org/10.1002/cncr.22080
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- p53 Expression as a Prognostic Marker in Inflammatory Breast CancerClinical Cancer Research, 2004
- Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapyThe Lancet, 2002
- Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph NodesJournal of Clinical Oncology, 2002
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Prognostic and predictive value of p53 and p21 in breast cancerBreast Cancer Research and Treatment, 1998
- Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cellsInternational Journal of Cancer, 1998
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNature Medicine, 1995
- Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Locally Advanced Breast Cancer: A Review Including the M.D. Anderson ExperiencePublished by Springer Science and Business Media LLC ,1991